Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pathology

Your Pathology Report: Decoding the Microscope

At a Glance

An intraductal breast papillomatosis pathology report shows whether the papilloma is benign, contains atypical cells such as ADH, or meets criteria for DCIS. Myoepithelial markers support interpretation but cannot be used alone to rule out cancer.

When you receive a pathology report for intraductal breast papillomatosis, you are looking at a translation of what a doctor (the pathologist) saw under a high-powered microscope. While the language can be dense, the report is essentially a map that tells your care team whether the growths are completely benign, “atypical,” or something more serious [1][2].

The Microscopic View: What Makes a Papilloma?

To a pathologist, a papilloma is a specific structural growth. They look for three main components to confirm the diagnosis:

  1. Papillary Architecture: This refers to the “finger-like” or “frond-like” shape of the growth [3].
  2. Fibrovascular Cores: These are the “skeletons” of the fingers. They are made of connective tissue and blood vessels that provide support and nutrients to the growing cells [1][4].
  3. Two-Layered Lining: A healthy papilloma is lined by two distinct types of cells: luminal epithelial cells lining the inner surface facing the duct, and myoepithelial cells forming the outer/abluminal layer underneath [3][5].

The Role of Myoepithelial Cells

The presence of myoepithelial cells helps define the architecture. In many types of invasive breast cancer, this outer layer of cells disappears or becomes broken.

To see these cells more clearly, pathologists often use special “tags” called myoepithelial markers (such as p63, p40, or calponin). However, these immunostains are not a definitive “safety barrier.” They support the pathologist’s interpretation but must be read with the cell morphology. In-situ lesions (like DCIS) may retain myoepithelial cells, and no marker by itself excludes carcinoma [6][7]. A breast pathologist integrates the architecture, cytology, and imaging context together.

Understanding the “Spectrum” of Results

Pathology is not always a simple “yes or no” answer. Instead, it is a spectrum of how the cells look and behave.

1. Papilloma Without Atypia (Benign)

This means the cells are growing in a mass, but they look like normal, healthy breast cells. This is a completely benign result [1].

2. Papilloma With Atypia (High-Risk Lesion)

“Atypia” means some of the cells have started to look unusual or “monotonous” [8].

  • Atypical ductal hyperplasia (ADH) is a common form of atypia. ADH is not cancer, but it is considered a “high-risk” finding because it is associated with a higher likelihood of an adjacent or future breast cancer [9][10].
  • Atypia may be found within the papilloma itself or in the adjacent breast tissue.

3. Ductal Carcinoma In Situ (DCIS)

If the unusual cells meet defined cytologic and architectural features, it is classified as DCIS. While DCIS is non-invasive (the malignant cells remain confined to ducts and have not invaded surrounding tissue), it is a cancer diagnosis and requires a distinct treatment plan [9][11].

No “Stage” or “Grade” for Benign Papillomatosis

If your diagnosis is benign intraductal papillomatosis or papilloma with ADH, you will notice that your report does not include a stage (like Stage 1 or 2) or a grade (like Grade 1, 2, or 3).

  • Staging is used only for cancer to describe how far it has spread [12].
  • Grading describes how aggressive cancer cells look under a microscope [13].
    Because benign papillomas and ADH are not cancer, these systems do not apply [14].

Pathology Report Checklist

When reviewing your report, ensure these key elements are addressed. If they aren’t, it’s a good reason to ask your doctor for more information.

  • [ ] Exact Diagnosis: Does it explicitly state “without atypia” or name a specific high-risk lesion like ADH?
  • [ ] Type of Procedure: Was this a core needle biopsy, a vacuum-assisted biopsy, or a surgical excision?
  • [ ] Calcifications: If the biopsy was for microcalcifications, does the report state that calcium was present in the tissue?
  • [ ] Surrounding Tissue: Does the report describe the health of the breast tissue around the papilloma? [15]
  • [ ] Concordance (For the Radiologist): Ask your breast team if the radiologist formally determined that the pathology matches the imaging. (This is usually not printed on the lab report itself) [16].

Common questions in this guide

What does a benign papilloma without atypia mean on a breast pathology report?
It means the pathologist found a papilloma whose cells look like normal breast cells and did not identify atypia. This is a benign, noncancerous result. The rest of the report and the match between the imaging and biopsy help the care team determine what the findings mean.
Is atypical ductal hyperplasia inside a papilloma cancer?
No. Atypical ductal hyperplasia, or ADH, is not cancer, but it is a high-risk finding linked with a higher chance of an adjacent or future breast cancer. The report should clarify whether the atypia is inside the papilloma or in nearby breast tissue.
What does DCIS mean when it appears with breast papillomatosis?
DCIS means the unusual cells meet criteria for ductal carcinoma in situ. It is a cancer diagnosis, but the malignant cells remain confined to the ducts and have not invaded surrounding tissue. It needs a treatment plan different from that for a benign papilloma.
Why does my pathology report mention myoepithelial cells or p63 and p40?
Myoepithelial cells form the outer layer around a breast duct and help the pathologist assess the structure of a lesion. Stains such as p63, p40, and calponin can make these cells easier to see, but no single stain proves or rules out carcinoma. The pathologist also considers cell appearance, tissue architecture, and imaging.
Should a benign papillomatosis pathology report include a cancer stage or grade?
Usually not. Staging describes how far a cancer has spread, while grading describes how aggressive cancer cells look under a microscope; these systems do not apply to a benign papilloma or ADH. DCIS is a cancer diagnosis and is evaluated separately.
How can I tell whether my needle biopsy matches the breast imaging?
Ask whether the radiologist documented imaging-pathology concordance, meaning the tissue result matches the area seen on imaging. Concordance may not appear on the laboratory report itself, and the breast team considers the procedure type, biopsy sample, and imaging together.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on intraductal breast papillomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my report mention 'usual ductal hyperplasia' or 'atypical ductal hyperplasia'?
  2. 2.If the biopsy was done for microcalcifications, does the report state that calcifications were present in the sample?
  3. 3.If atypia was found, was it located inside the papilloma itself or in the surrounding tissue?
  4. 4.Given that this was a needle biopsy, how confident are you that the sample represents the entire area seen on imaging?
  5. 5.Are there any terms in the report (like 'arborizing' or 'epithelial proliferation') that I need explained in more detail?

References

References (16)
  1. 1

    Papillary Neoplasms of the Breast: WHO Classification, Multimodality Imaging, and Radiologic-Pathologic Correlation.

    Thai JN, Vickery J, Boyraz B, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(8)):e240091 doi:10.1148/rg.240091.

    PMID: 40674246
  2. 2

    Pathological criteria and practical issues in papillary lesions of the breast - a review.

    Ni YB, Tse GM

    Histopathology 2016; (68(1)):22-32 doi:10.1111/his.12866.

    PMID: 26768027
  3. 3

    Classical Lobular Carcinoma In Situ Arising From an Intraductal Papilloma of the Breast: A Case Report.

    Kim NI, Park MH, Lee JS

    International journal of surgical pathology 2021; (29(5)):534-537 doi:10.1177/1066896920985216.

    PMID: 33403884
  4. 4

    Clinicopathologic features of intraductal papillary neoplasm of breast: analyses of three cases.

    Zhao Y, Li N, Gong X, et al.

    International journal of clinical and experimental pathology 2017; (10(9)):9575-9582.

    PMID: 31966834
  5. 5

    Spectrum of Papillary Breast Lesions According to World Health Organization Classification of Papillary Neoplasms of Breast.

    Hashmi AA, Faraz M, Rafique S, et al.

    Cureus 2020; (12(10)):e11026 doi:10.7759/cureus.11026.

    PMID: 33214954
  6. 6

    Encapsulated Papillary Carcinoma: A Case Report and Review of the Literature.

    Athanasiou A, Khomsi F, de Joliniere B, Feki A

    Frontiers in surgery 2021; (8()):743881 doi:10.3389/fsurg.2021.743881.

    PMID: 35187043
  7. 7

    Invasion in breast lesions: the role of the epithelial-stroma barrier.

    Rakha EA, Miligy IM, Gorringe KL, et al.

    Histopathology 2018; (72(7)):1075-1083 doi:10.1111/his.13446.

    PMID: 29197112
  8. 8

    Atypical Ductal Lesions of the Breast: Criteria, Significance, and Laboratory Updates.

    East EG, Carter CS, Kleer CG

    Archives of pathology & laboratory medicine 2018; (142(10)):1182-1185 doi:10.5858/arpa.2018-0221-RA.

    PMID: 30281370
  9. 9

    Ductal carcinoma in situ of the breast arising in a solitary intraductal papilloma.

    Badrawi N, AlSayegh AA

    Radiology case reports 2023; (18(2)):449-451 doi:10.1016/j.radcr.2022.11.014.

    PMID: 36439917
  10. 10

    Papillary lesions of the breast - review and practical issues.

    Ni Y, Tse GM

    Seminars in diagnostic pathology 2022; (39(5)):344-354 doi:10.1053/j.semdp.2022.06.001.

    PMID: 35718581
  11. 11

    Ductal Carcinoma in Situ: Current Concepts in Biology, Imaging, and Treatment.

    Shehata M, Grimm L, Ballantyne N, et al.

    Journal of breast imaging 2019; (1(3)):166-176 doi:10.1093/jbi/wbz039.

    PMID: 31538141
  12. 12

    Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.

    Doebar SC, van den Broek EC, Koppert LB, et al.

    Breast cancer research and treatment 2016; (158(1)):179-187 doi:10.1007/s10549-016-3862-4.

    PMID: 27318854
  13. 13

    Atypia in breast pathology: what pathologists need to know.

    Katayama A, Toss MS, Parkin M, et al.

    Pathology 2022; (54(1)):20-31 doi:10.1016/j.pathol.2021.09.008.

    PMID: 34872753
  14. 14

    Use of fiberoductoscopy for the management of pathological nipple discharge: ten years follow up of a single center in China.

    Zhang C, Li J, Jiang H, Li M

    Gland surgery 2020; (9(6)):2035-2043 doi:10.21037/gs-20-738.

    PMID: 33447554
  15. 15

    Pathology of breast papillary neoplasms: Community hospital experience.

    Vdovenko AA

    Annals of diagnostic pathology 2020; (49()):151605 doi:10.1016/j.anndiagpath.2020.151605.

    PMID: 32920473
  16. 16

    Pathologic High-risk Lesions, Diagnosis and Management.

    Murray M

    Clinical obstetrics and gynecology 2016; (59(4)):727-732 doi:10.1097/GRF.0000000000000234.

    PMID: 27681693

This page explains intraductal breast papillomatosis pathology terms for informational purposes only and does not constitute medical advice. Your pathologist and breast care team should interpret your report together with your imaging.